NANOGEN EXPLODIERT!!!!! - 500 Beiträge pro Seite

[tst89]

Hallo allerseits!!!

62,76% vorbörslich!!!

Hatte wohl mit meinen letzten Beiträgen recht!!!

tst

[gebby]

was geht da ab???? hab da noch ein paaar im depot liegen!!!!
sind aber trotz +60% noch weit vom einstandskurs weg....
aber, was waren eigentlich deine beiträge???
danke im voraus

[ramjam]

Könntest recht haben - die Kooperation mit dem Militär ist jetzt Gold wert!

ramjam

[tst89]

@gebby

schau mal unter "Nanogen und Aventis"
die letzten 4 Beiträge!!!!


@dagobert
Hoffe Du bist rechtzeitig eingestiegen!!!


@all

Heute morgen tipp ich rum dass es wegen der Kooperation
mit dem US Militär aufwärts gehen könnte!!!
Und jetzt dies!

Macht schon mal den Schampus auf!!!
Hier die gesamten News:
Wednesday October 10, 8:00 am Eastern Time

Press Release

SOURCE: Nanogen, Inc.

Nanogen Receives U.S. Army Grant to Develop Biowarfare Detection Systems

SAN DIEGO, Oct. 10 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that it has been awarded a
three-year, $1.5 million grant from the U.S. Army to continue development of miniaturized electronic devices for isolating and
detecting biological warfare and infectious disease agents from human blood samples. No live microorganisms associated with any
biological agents will be analyzed or handled at Nanogen`s facilities. The U.S. Army Medical Research Institute of Infectious
Disease at Fort Detrick, Maryland will supervise the research. This is the second `Dual Use Science and Technology` grant awarded
to Nanogen by the U.S. Army Medical Research Acquisition Activity, the first one commencing on October 5, 2000.

``This agreement represents our continued commitment to the advancement of biological warfare defense, namely developing
miniaturized electronic systems for rapidly detecting micro-organisms, DNA and protein substances that may be deployed as
biological warfare agents,`` said Randy White, Chief Executive Officer of Nanogen. ``Nanogen believes that its unique electronic
microarray technology is particularly well suited to these development efforts. Our specific aim is to further develop technologies that
will automate and integrate biological sample preparation, amplification and detection on the NanoChip® electronic microarray. In
addition, we aim to apply the technologies developed under this grant to Nanogen`s primary commercial efforts in molecular
diagnostic research and development.``

Nanogen`s goal is to be the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility
necessary to bridge the gap between the research and clinical settings. The Company is seeking to establish the NanoChip® System
as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the
Company has developed and internally validated a research protocol for the detection of the Factor V Leiden gene mutation
associated with cardiovascular disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics
laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional
information please visit Nanogen`s web site at www.nanogen.com.

The grant DAMD17-01-2-0022 was awarded by the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ft.
Detrick, Maryland 21702-5014. The information contained in this press release does not necessarily reflect the position or the policy
of the Government and no official endorsement should be inferred. This press release contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking
statements, including, whether the Company`s NanoChip® System can be successfully further commercialized, whether products
under development can be successfully developed and commercialized, whether results reported by our customers or partners can be
identically replicated, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing
additional assays, whether Nanogen will be successful in developing FDA cleared or approved molecular diagnostic tests utilizing the
NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere
in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange
Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to
update these forward-looking statements.

SOURCE: Nanogen, Inc.




Reuters Securities - 8:26 am

Wednesday October 10, 8:26 am Eastern Time

Nanogen gets grant for detection system development

SAN DIEGO, Oct 10 (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - news) on Wednesday said it has received a three-year, $1.5
million grant from the U.S. Army to continue development of its biological warfare detection systems.

Nanogen develops miniaturized electronic devices for isolating and detecting biological warfare and infectious disease agents from human blood samples.

The company said the U.S. Army Medical Research Institute of Infectious Disease at Fort Detrick, Maryland will supervise the research. It is the second such grant
Nanogen has received from the U.S. Army




at TheStreet.com - 9:25 am

Nanogen Rockets on Army Grant

By TSC Staff

10/10/2001 09:25 AM EDT

Nanogen (NGEN:Nasdaq - news - commentary - research) shares were up
$3.215, or 57.6%, in preopen Instinet trading after the company said it has
received a three-year, $1.5 million grant from the U.S. Army for continued
development biological warfare detection systems.

Nanogen said the U.S. Army Medical Research Institute of Infectious
Disease at Fort Detrick, Md. will supervise its research to develop
miniaturized electronic devices for isolating and detecting dangerous agents
in human blood samples.

It is the second such grant Nanogen has received from the U.S. Army, the company said.




Reuters Securities - 10:06 am


Wednesday October 10, 10:06 am Eastern Time

Hot stocks highlights -- Oct. 10

NEW YORK, Oct 10 (Reuters) - Stocks making significant moves in U.S. markets on Wednesday included:

CAPSTONE TURBINE CORP. (NasdaqNM:CPST - news) FELL $1.42, OR 28 PERCENT,

To $3.58

**The producer of microturbine power systems on Tuesday projected a wider-than-expected third-quarter loss.

Capstone said it expects to report revenue in the range of $3.2 million to $3.4 million and post a loss per share of between 16 cents and 18 cents, worse than the 12 cent
loss expected by analysts as polled by Thomson Financial/First Call.

The stock was the biggest loser in percentage terms on Nasdaq on Wednesday morning.

NANOGEN INC. (NasdaqNM:NGEN - news) ROSE $4.215, OR 75 PERCENT, TO $9.80

**The San Diego, California-based company said it has received a three-year, $1.5 million grant from the U.S. Army to continue development of its biological warfare
detection systems.

Nanogen develops miniaturized electronic devices for isolating and detecting biological warfare and infectious disease agents from human blood samples.

The company said the U.S. Army Medical Research Institute of Infectious Disease at Fort Detrick, Maryland will supervise the research. It is the second such grant
Nanogen has received from the U.S. Army.

The stock was the biggest net gainer on Nasdaq on Wednesday

[DagobertDag]

Nein

Bin erst jetzt nach Hause gekommen, jetzt ist schon alles gegessen. Wollte mir eigentlich mal in Ruhe überlegen, aber jetzt...... Jetzt steige ich auch nicht mehr ein.
Habe mir jetzt vor Frust Opticom gekauft zu 33,5Euro

Ich hatte schon mal eine Kauforder zu 21 abgegeben --> nicht zum Zuge gekommen um 0,50 Euro
Wollte Valora kaufen Limit bei 2,95 um einen Cent verfehlt letzter Kurs bei 4 Euro. Und das alles im Oktober.!!
So jetzt habe ich gekauft und wie ich die Sache sehe fällt dann alles wieder.
Wenn ich weiter so ein Pech mit meinen Kauflimits habe kaufe ich noch irgendeine blöde Aktie, so wie ich mich kenne.

gruß

[luto9]

Was ist passiert? Anfangsgewinne konnten nicht gehalten
werden. Hat jemand eine Ahnung, warum es kurz nach Eröffnung
nur noch abwärts ging?

[tst89]

@luto9

Ganz klar. Sind alles Gewinnmitnahmen gewesen. Überleg`
mal - vor ein paar Wochen war Nanogen bei 3,50$ - gstern
zeitweise bei 10$!!!

Über die nächsten Wochen hinweg sehe ich trotzdem eine
Aufwärtsbewegung.....

Gruß
tst

[rescue]

Darauf kannst du Anthrax nehmen... ;-) - Leider!

[tst89]

Diesen Beitrag in diesen Thread.....ihr sollt mal was zum lesen haben:

===================================
from Gilder Publishing
THE FRIDAY LETTER
e-mailed weekly, for friends and subscribers
===================================
| http://www.gilder.com/ |

Issue 29.0/October 12, 2001

HEADLINES:

* The Week/ Nanogen is all the Rage

One of the most talked about stocks this week has been Nanogen. At one
point, the stock was up over 50% after the company announced that it had
received a three-year, $1.5 million grant from the US Army for continued
development of biological warfare detection systems. Gilder Biotech
subscribers, of course, knew of Nanogen from Scott Gottlieb`s October
report, posted last week to http://www.gilderbiotech.com/. But Scott has
been quick to point out that it`s actually a small grant in the scheme of
the Army`s program and Nanogen`s balance sheet. Technology and innovation
is where it`s at, and that`s why Nick Tredennick also picked up on Nanogen
in his September issue of the Dynamic Silicon Report
(http://www.dynamicsilicon.com/)," target="_blank" rel="nofollow ugc noopener">http://www.dynamicsilicon.com/), describing Nanogen`s unique DNA analysis
chip, or "gene chip." Clearly an innovative company, so here are some
pertinent excerpts about their technology from the Biotech and Dynamic
Silicon reports:
From the Dynamic Silicon Report (http://www.dynamicsilicon.com/ ):
Nanogen (NGEN) builds a unique DNA analysis chip or "gene" chip. Nanogen`s
chip is an array of individual test sites. The current chip, housed in a
transparent, $175, "NanoChip" cartridge, contains 99 test sites. Primer
nucleotide sequences are bound to test sites. Test sites can have
different primers. Nanogen exploits the naturally occurring positive or
negative charge of most biological molecules. Addressing a particular
primer test site with an electric charge attracts DNA molecules to the
test site, speeding processing from hours to minutes. DNA molecules
containing a complementary nucleotide sequence bind with (anneal to) the
primer.

[tst89]

Ich glaub in Zukunft kommen in diesen Thread die ganzen News die
ich finde und meine Meinungen und Kommentare in den anderen aktuellen.

Hier die Fortsetzung der letzten News (achtet mal bitte auf den letzten Absatz - da wo es um die Zahlen geht....vor allem die 1 Mrd. US $!!):

From the Gilder Biotech Report (http://www.gilderbiotech.com/):
Like Motorola`s eSensor DNA Detection System, Nanogen`s NanoChip
technology also makes use of bioelectricity, but this time also to
customize the chip. The NanoChip is fast -- about 1,000 times faster than
Affymetrix`s GeneChip, generating results in just a few minutes compared
with hours or days for the latter`s passive hybridization process. Like
the eSensor DNA Detection System, Nanogen has ingeniously designed a way
to use DNA`s natural electrical properties to bring DNA probe and test
site together, quickly and efficiently.
How do they do it? DNA naturally has a negative electrical charge. To
move the DNA sample directly to a particular test site probe, the NanoChip
gives a charge to the DNA probes on the chip, a process called electronic
addressing. The negatively charged patient DNA samples leap to the
positively charged DNA probe sites, where they are concentrated and bound
by a chemical process. Wash off the biochip and another solution of
distinct DNA probes may be added, activating different test sites. Site by
site, row by row, users can assemble or address a custom array of DNA
probes on the microchip in a user-defined order. The process is entirely
automated.
NanoChips are also highly accurate, more accurate than Affymetrix systems
in studies I`ve reviewed. Affymetrix`s passive hybridization system
increases the possibility that, in rare instances, a patient`s DNA sample
will not fully saturate the chip, creating a false negative. Affymetrix`s
GeneChips also allow some samples of DNA to bind to probes that aren`t
really complementary, giving false positives. In published studies,
Nanogen`s active hybridization results in a remarkable 100 percent
accuracy rate. Faster diagnosis with 100 percent accuracy -- for clinical
applications, that is a techno-edge hard to beat.
Nanogen`s current revenues are about $20 million. In a time of rapid
technological development, market cap is hard to estimate. But here is a
conservative estimate: DNA diagnostics (including PCRs) currently account for about $500 million of that $20 billion market. The current market for
microbiology tests (blood cultures, etc.) is about $1.3 billion alone
growing at 5 percent a year. If Nanogen captures one-fifth of that
combined market, that would bring it more than $1 billion in sales.

[tst89]

So eine Meldung nach Börsenschluß ist ok
Denke heute müssten wir an die 10$-Marke kommen.



Monday October 15, 10:12 pm Eastern Time

Press Release

SOURCE: Nanogen, Inc.

Nanogen at UBS Warburg Investor Conference: Discusses Progress in Development Of Its Molecular Diagnostics, Biowarfare and Human Identification Programs

SAN DIEGO, Oct. 15 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today its progress in the development of its molecular diagnostics, biological warfare and human identification programs as highlighted in the Company`s presentation at the UBS Warburg Global Life Sciences Healthcare Conference, which took place on Friday, October 12, 2001.

Genetic Research and Pathway to Molecular Diagnostics

In the conference, Nanogen discussed the advantages of its core technology and how the Company believes that it may leverage its technological strengths to become a leading supplier of analytical devices to the genetic research market and eventually molecular diagnostic tests to the clinical diagnostic market. Nanogen stated it is the only company that has a commercial product on the market, the NanoChip® System, that uses electronically enhanced hybridization of complementary DNA strands.

Nanogen plans to obtain the necessary regulatory approvals to allow its technology, currently used by research institutions and clinical research laboratories, to be used in the molecular diagnostics market. In that market, quality, operational simplicity and cost effectiveness are important adoption criteria for new technology. Nanogen said that it believes it has met those criteria in the research setting, and will focus its efforts on demonstrating the applicability of those advantages to the molecular diagnostics field.

The Company reiterated that in a significant number of research studies to date, the NanoChip® System has achieved 100% accuracy in the detection of SNPs. In addition, these studies have demonstrated the system`s flexibility and speed of analysis. A customer study has also shown advantages in consumable costs as compared to a competing technology. Moreover, Nanogen`s technology allows researchers to perform ``multiplex`` assays (the ability to run assays that determine the presence or absence of multiple genetic mutations at the same time and on the same chip). Nanogen is currently developing technology to allow the on-chip amplification of DNA material directly on the NanoChip® cartridge, which if successful, eliminates a time- consuming preparatory step and folds it into a single, simplified detection procedure. Nanogen believes these advantages will make its technology an attractive candidate for the molecular diagnostics market.

Nanogen has already launched an internally validated research protocol for Factor V Leiden, seeks to add four other such protocols by the end of the year, and has other protocols under development. It plans to introduce analyte specific reagents or ASRs early in 2002 and then work towards obtaining regulatory clearance or approval for molecular diagnostic tests, including petitioning for uniquely applicable reimbursement codes.

Biological Warfare and Human Identification Activities

Nanogen has received a number of U.S. government grants to further its biowarfare and human identification programs. Nanogen has been working on its biowarfare and human identification programs with U. S. governmental agencies since 1997. Nanogen has created and delivered to the U.S. Government a prototype portable field-based detection device and is currently developing additional devices and assays for detecting biowarfare agents and infectious diseases. Nanogen is working towards a self-contained portable system where the amplification and detection of DNA can occur quickly to enable the rapid testing of potential biowarfare threats.
The Company is also using certain government funding to further develop applications relating to the use of short tandem repeats (STRs) and single nucleotide polymorphisms (SNPs) for forensics and other human identification purposes.

Specific current development efforts include three grants from The Defense Advanced Research Projects Agency to develop an integrated microlaboratory and assay protocols to analyze simulated biowarfare targets. In addition, Nanogen has two Dual Use Science and Technology grants administered by the U.S. Army to develop assays and associated hardware for detecting biowarfare agents and infectious diseases. Nanogen also has a grant through the National Institute of Justice for the development of forensic tools relating to the use of STRs and SNPs. In addition, included in the third quarter placements previously announced, Nanogen sold a NanoChip® System to a government institution that is interested in developing STR and SNP assays for criminal identification purposes.

``Nanogen has received over $14.5M in government funding and commitments to support its biowarfare and human identification efforts. The grants and investments Nanogen makes in biowarfare helps support our primary goal of providing advanced solutions for medical diagnostics,`` said Randy White, Chief Executive Officer of Nanogen.

Nanogen`s goal is to be the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap
between the research and clinical settings. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations
and to develop applications for future clinical use. To date, the Company has developed and internally validated a research protocol for the detection of the Factor V
Leiden gene mutation associated with cardiovascular disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics
laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s
web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth
in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether products under
development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether
regulatory clearances or approvals will be obtained, whether the patented inventions can be successfully incorporated into commercial products, whether Nanogen will
be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption
``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these
forward-looking statements.

SOURCE: Nanogen, Inc.

[tst89]

Hier einige Auszüge aus der Präsentation vom 12.10.
bei der UBS Warburg Inverstor Conference (daraufhin hat übrigens UBS NGEN auf STRONG BUY geratet! - wer Interesse an
der kompletten Präsentation hat ---> www.nanogen.com, dann
auf der Hauptseite auf den unten durchscrollenden Text klicken!)

Nanogen at UBS Warburg Investor Conference: Discusses Progress in Development Of Its Molecular Diagnostics, Biowarfare and Human Identification Programs

Investing in Nanogen

Markets:
Discovery/High Throughput Screening - clear leaders exist
Clinical Research Transitions Toward Clinical Diagnostics – Nanogen Focus
Growing market $1 billion today? $3 billion in 2005
No established leader

NGEN: THE electronic biochip
Platform technology
Targeted for development of Clinical Diagnostics
Strong Intellectual Property Position
Thirty one (31) Issued U.S. Patents
Eighteen (18) Issued Foreign Patents
Numerous Patent Applications Pending

Motorola Litigation Settled Favorably
Freedom to Operate Under “939”
No Cross License of NGEN Technology
Significant Legal Fee Expense Reduction

Product Launch Schedule Beginning Q-3
Five (5) Research Use Protocols by 12/31/01



Bis 2005 wird sich der Umsatz in dieser Branche also
verdreifachen!!!! Gute Zeiten also für Nanogen-long
Investierte!!!

Gruß
tst

[tst89]

10/16/01 08:32 am; Small Times

SMALL BIOTECH COMPANIES` STOCK
SURGES WITH U.S. DEFENSE CONTRACTS
By Richard Acello
Small Times Correspondent

The recent alarm over the threat of biowarfare has thrust Nanogen, a San Diego-based biotech, and a handful of other technology firms into the spotlight as the nation scrambles to assemble a readily available biowarfare defense plan.

On Wednesday, shares of Nanogen shot up almost 50 percent to $8.33 on news that the company won a three-year contract from the U.S. Army, valued at $1.5 million. The military is a relatively recent client addition for Nanogen (Nasdaq: NGEN), whose traditional customer base includes Johns Hopkins University and the National Cancer Institute.

Nanogen`s part of the puzzle is the creation of a miniature electronic device
Nanogen received a $1.5 million contract
from the U.S. Army to develop a
battlefield version of its "NanoChip"
system to detect biological attacks.for isolating and detecting biological warfare and infectious disease agents from blood samples that would be part of the front line defense in a bio attack. "The intention is to create a simple, easy-to-use system that can be used in the field, in a doctor`s office, most likely by a nurse," said Kieran Gallahue, president of Nanogen. Gallahue said the "sample to answer" system would be able to yield results in less than 24 hours.

The technology for the blood analysis is based on Nanogen`s "NanoChip" system that analyzes genes, also known as molecular diagnostics, and applies the findings to clinical research. The NanoChip allows computer-assisted blood analysis, or as Gallahue put it, "DNA analysis on a microchip." The company markets its NanoChip Molecular Biology Workstation to genomics laboratories and research facilities.

Though the terrorist attacks have changed the nation`s consciousness about biological warfare, Nanogen announced a $1.1 million Army grant in October of last year, to much less fanfare. These are in addition to prior grants totaling $15 million from the National Institute of Justice (NIJ) and the Defense Advanced Research Projects Agency DARPA) for both law enforcement and defense purposes.

Nanogen went public in 1997 with a $64 million offering and raised $82 million in a secondary offering last year. Nanogen closed Monday up 51 cents (5.92 percent) to $9.12 and traded as high as $9.80 during the session on about 5 times average volume. The 52-week range is $3 and $20.43.

"Our primary business is clinical research," said Gallahue. "Our long-term mission is electrodiagnostics for health care applications. But grants like this are important, because core research gets funded by a defense grant and we can apply it to health care."

A biotech analyst agreed. "Any free money like that is a win for shareholders," said John McCamant, editor of the Medical Technology Stock Letter, based in Berkeley, Calif. "And a couple of million dollars really makes a difference for some of these $100 to $150 million market cap companies." Nanogen has a market cap of $150.4 million.

McCamant noted the sharp Wednesday runup for Avant Immunotherapeutics, which doubled after announcing that it would license vaccine technology to DynPort Vaccine Co., which has a contract with the U.S. Department of Defense.

Such wild swings will be typical of companies in the emerging biotech to high-tech arena, characterized by short-term profits that the biodefenders may not be able to hold, the biotech analyst said.

"It`s not a sustainable business model," McCamant explained. "But it is a real business, including the whole detection business (for safety) of air, food and water." Nanogen`s "sample to answer" system is not yet in product form and Gallahue did not provide a release date.

[tst89]

Und noch was: Ein neues Patent!

United States Patent 6,303,082
October 16, 2001
Permeation layer attachment chemistry and method
Electronically addressable microchips having covalently bound permeation layers and methods of making such covalently bonded permeation layers to microchips are provided. The covalent bonding is derived from combining the use of electrodes with silane derivatives. Such chemistry provides the ability to apply an electronic bias to the electrodes of the microchip while preventing permeation layer delaminating from the electrode surface.
Inventors: John; Havens R. (San Diego, CA); Winger; Theodore M. (San Diego, CA); Krotz; Jain (San Diego, CA); Dan; Smolko (Jamul, CA);
Onofrey; Thomas J. (San Marcos, CA)

Assignee: Nanogen, Inc. (San Diego, CA)

[tst89]

Hat zwar nicht direkt was mit Nanogen zu tun, könnte aber bald was werden

Ist ein Artikel aus der New York Times:

The Senate moved to develop legislation that would provide as much as $10 billion to deal with the threat of bioterrorism. The legislation would allocate much more money than the Bush administration has sought to buy drugs and vaccines and to increase the capacity of hospitals, laboratories and state and local government agencies to respond to bioterrorist attacks. The money could be used to buy medical supplies and to train health care workers to treat the victims of an attack.

On Wednesday, the Bush administration requested $1.5 billion to help the Department of Health and Human Services combat bioterrorism. The Defense Department is also seeking hundreds of millions of dollars, though the precise amount is not clear.


______________

1,5 Mrd. $ gegen die Bekämpfung von Terrorismus.....
vielleicht bekommt ja Nanogen auch was vom Kuchen
ab.....wäre ja nicht dass erste mal

tst

[tst89]

Ein weiteres Patent und bereits fast +10% an der Nasdaq:

United States Patent 6,306,348
Havens , et al.
October 23, 2001
Inorganic permeation layer for micro-electric device
Abstract
The present invention pertains to a method of, and a device created by, depositing an inorganic permeation layer on a micro-electronic device for molecular
biological reactions. The permeation layer is preferably sol-gel. The sol-gel permeation layer can be created with pre-defined porosity, pore size distribution, pore morphology, and surface area. The sol-gel permeation layer may also function as the attachment layer of the micro-electric device.
Inventors: Havens; John R. (San Diego, CA); Krihak; Michael K. (San Diego, CA); Greef; Charles H. (Ramona, CA); Raymond; Daniel E. (San Diego, CA); Heller; Michael J. (Encinitas, CA)

Assignee: Nanogen, Inc. (San Diego, CA)

[swoasik]

Hallo an Alle!
Habe soeben Nanogen zu 9,40 (1500Stck.)gekauft.
Wie seht ihr die Zukunft der Aktie.Habe leider nicht so viel Ahnung"(war mehr ein Instinkt)" .Über Antworten
würde ich mich sehr freuen.
Ps.wie ist diese Firma vom Finanzellen gestellt??
Danke! Swoasik@

[tst89]

@swoasik

Wilkommen im Club!
Die finanziellen Reserven der Firma sind enorm (die Cash-Reserven belaufen sich auf 78 Mio. US $!!!), aber schau einfach diesen Thread und den "Nanogen und Aventis"-Thread durch dann weißt Du eigentlich schon mal dass Grundlegende was die letzten Monate passiert ist.

Gruß
tst

@ambobobo & dagobert
was los mit Euch?? Ihr seid so ruhig....

[swoasik]

Danke an tst89@
Werde versuchen mich da Schlau zu machen.Danke für die
Aufnahme im Nanogen-Club,hoffe das auch ich was beitragen
kann."Und bei 50$ machen wir eine kleine Feier"
Swoasik@

[DagobertDag]

Hallo tst89

Hatte mein letztes Geld in Adva( da bin ich noch rechtzeitig rein)investiert, und bin voll in Opticom drinn.
Finde Nanogen zwar gut, aber nachdem mich überall die Kurse weggelaufen sind wollte ich nicht hinterher hecheln.



@ swoasik
Dein investment ist nicht verkehrt. aber normalerweise macht man es andersherum. Man Informiert sich zuerst und steigt dann ein.


Noch etwas anderes.
wenn man sich die Boards beim Neuen Markt so ansieht kann man wirklich nur sagen. DIES IST EIN KLASSE BOARD

Gruß und

[swoasik]

@Dagobert Dag
Hallo,du hast ja so Recht,aber da bei mir Geld frei wurde
und ich eueren wirklich guten Bord schon länger im Auge habe
"eben wegen dieser Aktie" und euer Bord ist wirklich Klasse
habe ich eben nicht lange gezögert sondern gekauft.
Macht weiter so!!
@Swoasik

[luto9]

nanogen bringt 31.10 Zahlen.
Gruß

[tst89]

Hier nochmal alles:




Wednesday October 31, 4:01 pm Eastern Time

Press Release

SOURCE: Nanogen, Inc.

Nanogen Reports 2001 Third Quarter Results; Achieves Record Product
Revenues for Quarter

SAN DIEGO, Oct. 31 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced its financial results for the
third quarter ended September 30, 2001.

Product revenues for the third quarter of 2001 were $1.0 million, an increase of 88% over the third quarter last year and more than
three times the second quarter of 2001. During the current quarter, Nanogen sold seven NanoChip® Molecular Biology
Workstations and additionally entered into three non-title transfer transactions under new Development Site Agreements. Total
revenues for the quarter ended September 30, 2001 were $3.2 million compared to $3.5 million for the same period in 2000. The
decline in total revenues was due to an anticipated decrease in revenues earned in connection with sponsored research programs
as the Company`s revenue base transitions from primarily sponsored research revenues to product revenues.

For the first nine months of 2001, product revenues were $1.6 million, as compared to $709,000 for the first nine months of last
year. For the first nine months of 2001, total revenues were $8.9 million as compared to $8.2 million for the same period in 2000.
Revenue recognized during the nine months ended September 30, 2001 was primarily earned under sponsored research programs
from the Company`s corporate alliances and from contracts or grants with government agencies.

The Company`s cash, cash equivalents and short-term investment balance at September 30, 2001 was $75.1 million. Total
operating expenses for the third quarter of 2001 were $11.9 million, as compared to $9.9 million for the same period in 2000. For
the first nine months of 2001, total operating expenses, excluding charges totaling $6.4 million related to the defense and settlement
of a patent litigation matter, were $31.5 million compared to $24.3 million for the same period in 2000. The increases in operating
expenses for both the third quarter of 2001 and for the first nine months of 2001, as compared to the same periods in 2000, were
primarily due to increased sales and marketing expenses as the Company expanded its sales and marketing organization.

The reported net loss for the quarter ended September 30, 2001 was $7.0 million, or $0.33 per share compared to a net loss of
$4.6 million, or $0.22 per share for the same period in 2000. For the first nine months of 2001, inclusive of the defense and
settlement charges noted above of $6.4 million, the Company reported a net loss of $25.0 million or $1.20 per share. For the nine
months ended September 30, 2001, excluding the defense and settlement charges noted above of $6.4 million, the Company
reported a net loss of $18.6 million or $0.89 per share, compared to a net loss of $12.4 million or $0.62 per share for the same
period in 2000.

Highlights for the third quarter ended September 30, 2001 include:

-- The development and internal validation of the Company`s first
DNA-based research protocol, for Factor V Leiden, a mutation associated
with cardiovascular disease and the research pathology of thrombosis,
for use on the NanoChip(R) Molecular Biology Workstation.
Additionally, since the end of the quarter, the Company has also
announced the internal validation for two additional research
protocols. The first was for Factor II (Prothrombin), also a key
marker in the detection and risk assessment of certain cardiovascular
disorders, and the second was for a multiplexed format
Factor II/Factor V gene mutation combination at a single location on
the NanoChip(R) electronic microarray.

-- The resolution of the Company`s litigation with Motorola, Genometrix
and MIT by securing a license from Motorola to certain claims of U.S.
Patent No. 5,653,939 entitled "Optical and Electrical Methods and
Apparatus for Molecular Detection." This provides Nanogen the freedom
to operate under these claims, which relate to electronic
hybridization. Nanogen resolved the litigation without providing
access to Nanogen`s own technology and on favorable terms. To its
knowledge, Nanogen remains the only current provider of commercially
available electronic-aided hybridization products.

-- The awarding of an additional five United States patents broadening the
Company`s already strong patent portfolio and bringing the Company`s
total number of issued patents as of October 31, 2001 to 35 in the
United States and 21 abroad. The patents awarded to the Company since
the end of the third quarter include two additional patents relating to
the Company`s permeation layer technology.


Additionally, Nanogen recently announced that it had been awarded a three-year, $1.5 million grant from the U.S. Army to develop a miniaturized electronic device
for isolating and detecting biological warfare and infectious disease agents from human blood samples.

``We are delighted to have had a record quarter for product revenues. The initiatives we have taken to accelerate our planned entry into the clinical diagnostics
market are achieving their desired results,`` said Howard C. Birndorf, Executive Chairman and Co-Founder of Nanogen. ``The organization is delivering on our
commitment to expand the NanoChip® System`s menu, a critical indicator of the system`s flexibility and market appropriateness.``

Webcast of Conference

Nanogen management will hold a conference call to discuss third quarter financial results today at 4:30 p.m. Eastern Time. A live webcast is available via Nanogen`s
website at http://www.nanogen.com. A telephone replay of the conference call also will be available for 48 hours at 800-428-6051 (domestic) or 973-709-2089
(international), passcode ID #214039. The webcast will be available on Nanogen`s website through November 14, 2001.

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the
gap between the research and clinical settings. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic
mutations and to develop applications for future clinical use. To date, the Company has developed and validated research protocols for the detection of the Factor II
and Factor V Leiden gene mutations and a multiplexed format Factor II/Factor V gene mutation combination, all associated with cardiovascular disease. Nanogen
markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not
for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set
forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under
development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether
Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be
successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip®
System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year
ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
The Company disclaims any intent or obligation to update these forward-looking statements.

NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

September 30, December 31,
2001 2000
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $14,249 $55,330
Short-term investments 60,816 39,759
Accounts receivable 3,581 1,322
Inventory 4,212 2,289
Other current assets 2,534 1,689
Total current assets 85,392 100,389

Property and equipment, net 5,556 5,373
Acquired technology rights, net 4,339 5,179
Other assets 1,286 63
Restricted cash 114 164
$96,687 $111,168

LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $943 $1,223
Accrued liabilities 3,730 4,095
Deferred revenue 681 360
Current portion of capital lease obligations 1,191 2,011
Total current liabilities 6,545 7,689

Capital lease obligations, less current portion 1,720 1,565
Other long-term liabilities 1,669 500
Total long-term liabilities 3,389 2,065

Minority interest in consolidated subsidiary 4,800 --

Stockholders` equity:
Convertible preferred stock, $.001 par
value, 5,000,000 shares authorized;
no shares issued and outstanding at
September 30, 2001 and December 31, 2000 -- --

Common stock, $.001 par value,
50,000,000 shares authorized; 21,435,211
and 20,913,151 shares issued and
outstanding at September 30, 2001 and
December 31, 2000, respectively 21 21
Additional paid-in capital 197,630 193,459
Accumulated other comprehensive income 1,432 270
Deferred compensation (199) (325)
Notes receivable from officers (970) (1,099)
Accumulated deficit (115,961) (90,912)
Total stockholders` equity 81,953 101,414
$96,687 $111,168


NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)

Three months ended Nine months ended
September 30, September 30,
2001 2000 2001 2000
Revenues:
Sales $1,023 $545 $1,554 $709
Sponsored research 1,828 2,565 6,229 6,132
Contract and grant revenue 368 436 1,091 1,370
Total revenues 3,219 3,546 8,874 8,211

Operating expenses:
Cost of sales 727 437 1,127 450
Research and development 4,824 5,445 14,023 14,202
Selling, general
and administrative 6,194 4,026 16,386 9,651
Litigation and settlement
of patent matter 123 -- 6,432 --
Total operating expenses 11,868 9,908 37,968 24,303
Loss from operations (8,649) (6,362) (29,094) (16,092)

Interest income, net 1,019 1,783 3,437 3,722
Minority interest in loss
of consolidated subsidiary 485 -- 485 --
Gain on sale of investments 116 -- 116 --
Gain on foreign currency
transactions 9 -- 7 --
Net loss $ (7,020) $ (4,579) $ (25,049) $ (12,370)

Net loss per share -
basic and diluted $(0.33) $(0.22) $(1.20) $(0.62)

Number of shares used in
computing net loss per
share - basic and diluted 21,206 20,360 20,898 19,797

SOURCE: Nanogen, Inc.


___________________________


Ich persönlich halte die Zahlen für nicht so schlecht da Entwicklungen viel
Geld kosten und man im Hinterkopf haben sollte wieviel Geldreserven
Nanogen hat!

Gruß
tst

[tst89]

Ein interessanter Bericht:



Thursday November 1, 7:04 am Eastern Time

Press Release

SOURCE: Burill & Company

Biotech Stocks Rebound in October

Bioterrorism Keeps the Industry in the Limelight

SAN FRANCISCO, Nov. 1 /PRNewswire/ -- Fears about bioterrorism rose dramatically during October as sophisticated forms
of anthrax were discovered in letters sent to several members of the media and individuals within branches of the U.S. government.
The incidents have sparked tremendous concern, not only regarding anthrax, but also the threat of other bioweapons being
released onto the public. The current emphasis on prevention, detection, and potential treatment of illnesses caused by bioterrorist
activities has kept the focus on the biotech sector steadily during the month and the overall effect on stocks has been positive.

``Biotech has more than held its own during a `recovering` month for most of the market,`` noted G. Steven Burrill, CEO of Burrill
& Company, a San Francisco-based life sciences merchant bank. ``With consumer confidence worse than it has been in seven
years and the economy receding at 1% annual rate, many segments of the market took a beating, but biotech took center stage as
part of the nation`s hope against biowarfare.``

The Burrill Biotech Select Index gained 17% for the month (down 28% YTD) while the NASDAQ was up nearly 13% for the
month (down 31% YTD) and the DOW gained just under 3% in October (off nearly 16% YTD).

``The slight rally we saw early in the month was undermined by a growing sense of insecurity, both global and domestic,`` said
Burrill. ``Clearly, though, investors realize that biotech has an increasingly important role to play in today`s unsettled world.``
Indeed, Cepheid, which makes portable detectors of food and water contaminants, including anthrax and smallpox, has attracted a
great deal of interest with stocks soaring nearly 300% since the September 11 terrorist attacks and up 178% for the month. Other
firms have seen major gains as well. BioReliance, a company that makes a smallpox vaccine, has experienced 117% increase in
share prices since September 10, 2001. Nanogen`s shares rose 86% during October. The company, which has received over
$14.5 million in government funding and commitments to support its biowarfare and human identification efforts, has created and
delivered to the U.S. government a prototype portable field-based detection device and is currently developing additional
products, including assays, for detecting biowarfare agents and infectious diseases.

``... But, there`s more to the rebound than bioterrorism,`` Burrill commented. ``Many biotech stocks were trading at or near cash
value at the start of the month, offering investors low cost of entry with a large potential upside since the industry`s fundamentals
remain strong,`` he explained. ``Then, too, a number of companies including Affymetrix (up 87%), Calypte Biomedical Corporation
(up 60%), Orchid Biosciences (up 83%), Matritech (up 91%), and Ariad Pharmaceuticals (up 60%), had news worthy of
sparking major investor interest.

Affymetrix, with its stock up 87% for the month, announced a narrower third-quarter loss ($1.8 million, excluding special charges)
than analysts expected and projected 2002 revenue growth of 25% over an expected total of $190 million this year. In addition,
Affymetrix is extending its genetic technology beyond health care into the area of nutraceuticals. Nestle S.A. is using Affymetrix` gene chips to explore nutrition on a
molecular level to develop healthier products.

Affymetrix also announced a co-development agreement with Millennium, whereby the two companies would create a new generation of GeneChip® technology
designed to speed the drug development process. Millennium`s shares gained 43% during the month.

Another huge gainer during October was Odwalla, the maker of Fresh Samantha juices. The world`s number one soft drink company, Coca-Cola, agreed to pay
about $181 million-a premium of $50 million over its market cap of $131 million. Odwalla`s stock increased by 143% during the month. ``This deal addresses the
consumer`s desire for juice and soy-based beverages as an alternative to soft drinks,`` said Burrill. ``The move enables Coca-Cola to migrate further into the health
foods arena-a segment that is expected to prosper in our wellness-oriented future,`` he commented. ``Nutraceuticals is once again an attractive place to invest.``

Another area that experienced growth was diagnostics. The Burrill Diagnostic Fund was up nearly 13% for the month (down 19% YTD), with some players doing
exceptionally well. Cepheid, Orchid BioSciences, Inc., Myriad, Third Wave Technologies, Inc., Digene Corporation, Quidel Corporation, and Bio-Rad Labs all
posted significant double-digit gains. ``Calypte has posted third quarter revenues that are 75% higher than the same period last year,`` explained Burrill. ``The sale of
the company`s HIV-1 Western Blot serum assay more than doubled and with blood donations across the country reaching record levels, that demand can only
increase.``

The Burrill Genomics Index grew by almost 30% during the month (down 43% YTD). In addition to stellar performances by Affymetrix, Nanogen, and Millennium,
Human Genome Sciences` stock gained 38% despite a widening third- quarter loss and Caliper Technologies` stock climbed 27%, after the company posted
third-quarter revenues of $6.6 million, compared to $5.5 million a year ago.

The Burrill Large-Cap Index gained 14% (down 18% YTD). Genentech, beating Wall Street`s earning estimates by a penny, saw a 19% increase during the month.
Sales of the company`s anti-cancer drug, Rituxan®, which Genentech developed with IDEC Pharmaceuticals, were $212.8 million-a 13% increase over second
quarter sales. Genentech also announced increased sales of Herceptin® and Pulmozyme®.

The Burrill Mid-Cap Index was up 19% for the month (down 26% YTD). The majority of the companies posted healthy double-digit growth. In addition to Orchid,
EntreMed (up 35%), Ligand Pharmaceuticals (up 47%) and Transkaryotic Therapies (up 40%) all turned in strong performances.

The Burrill Small-Cap Index gained nearly 15% during October (down 14% YTD). Matritech, Inc. experienced a 90% gain on news that a prostate cancer market
identified by the company`s scientists detected prostate cancer with greater sensitivity than the prostate specific antigen (PSA) test. Shares of Ariad Pharmaceuticals
gained 60% during the month, based largely on the company`s announcement of the discovery of experimental compounds that could potentially be used to fight
cancer. Boston Life Sciences also posted gains of 67%.

The Burrill Nutraceuticals Index, bolstered in large measure by the Coca- Cola/Odwalla deal, gained 8%. Cyanotech, the world leader in producing microalgae
products posted a 54% increase for the month. While sales were lower, during the first six months of the fiscal year, the company saw sales of its packaged
consumer products increase by more than 60%. Integrated Health Technologies (up 21% for the month) has had a healthy upswing in sales. During the fourth
quarter, sales increased by 90% for the same period a year ago, signaling what the company believes is the trend for the future.

The Burrill Agbio Index gained only 3% (down 20% year to date). Bionova Holding Corporation (down 56%) and EDEN Bioscience Corporation (down 38%)
were the biggest losers.

A review of the Burrill Life Sciences Indices for August 2001 is as follows:

Index 12/31/00 9/30/01 10/31/01 Percent Percent
Value Value Value Change Change
for YTD
Month
Burrill Life
Science Composite
Index 183.2 139.63 155.47 11.34% -15.14%
Burrill Biotech
Select Index 412.97 253.31 296.85 17.19% -28.12%
Burrill LARGE-CAP
Biotech Index 387.93 275.24 315.31 14.56% -18.72%
Burrill MID-CAP
Biotech Index 284.78 176.06 209.62 19.07% -26.39%
Burrill SMALL-CAP
Biotech Index 187.79 140.04 161.25 15.14% -14.13%
Burrill Agbio
Index 87.64 67.55 69.64 3.10% -20.54%
Burrill Animal
Health Index 96.87 114.25 120.75 5.69% 24.66%
Burrill Genomics
Index 421.53 183.93 238.80 29.83% -43.35%
Burrill Bioma-
terials/
Bioprocess
Index 132.04 101.73 100.62 -1.10% -23.80%
Burrill Diagnostic
Fund 100 71.52 80.69 12.82% -19.31%
Burrill
Nutraceuticals
Index 105.36 102.55 111.07 8.31% 5.42%


Index 12/31/00 9/30/01 10/31/01 Percent Percent
Value Value Value Change Change
for YTD
Month
Burrill Biotech
Select Index 412.97 253.31 296.85 17.19% -28.12%
NASDAQ 2471.43 1498.80 1690.20 12.77% -31.61%
DJIA 10787.99 8847.56 9075.14 2.57% -15.88%
Russell 2000 483.53 404.87 428.17 5.75% -11.45%




Burrill & Company

Burrill & Company is a life sciences merchant bank, focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, human healthcare,
related medical technologies, agricultural technologies, animal health, nutraceuticals, and biomaterials/bioprocesses.

Venture Capital

The Burrill family of venture capital funds, with over $325 million under management, includes the Burrill Biotechnology Capital Fund, the Burrill Diagnostics Fund,
the Burrill Agbio Capital Fund, the Burrill Nutraceuticals Capital Fund, the Burrill Biomaterials/Bioprocess Capital Fund and the Burrill Life Science Capital Fund,
currently under development.

Strategic Partnering

Burrill & Company assists life science companies identify, negotiate and close strategic partnerships providing access to resources, technologies or collaborations
essential for executing their business plans. We have completed more than 20 strategic partnerships with a value in excess of $1 billion.

Spin-outs/Spin-ins

Burrill & Company works with major life science companies to spin-out internal assets and capitalize on their value, ranging from the outright sale of products or
businesses to creation of new companies to exploit these assets. We also use our extensive network to help companies identify, assess and capture (``spin-in``)
products and companies strategic to building their businesses.

For more information, please visit Burrill & Company`s website at www.burrillandco.com.

SOURCE: Burill & Company

[tst89]

Und noch was nettes:

A small group of biotechnology companies uses nanotechnology to manufacture microchips with a molecularly thin plastic coating. The coating protects the chip from liquid DNA samples and allows nanoparticles, such as negatively charged DNA, to move around the chip in response to electrical charges. The DNA is analyzed by determining which samples bind electronically to complementary DNA located on the chip. Although individual companies` methods vary, most allow scientists to analyze multiple samples simultaneously.
One such company is Nanogen (NASDAQ:NGEN), which Leheny said has developed technology that "can look at single-based differences in someone`s DNA." Leheny described Nanogen`s microarray technology as "in a launch mode." She said users of the technology have been "very, very impressed" and that diagnostics and medical research labs are likely to purchase it.
Kieran Gallahue, President of Nanogen, said his company`s technology can shorten many diagnostic decisions from days to minutes or hours, and provide information on whether, for example, a patient can metabolize an antibiotic properly.
Nanogen`s first product is the NanoChip Molecular Biology Workstation, which Gallahue described as "a couple of instruments that are combined with a credit card microchip-based consumable." He said researchers can use the equipment to design genetic analyses "as they see fit." Gallahue expects Nanogen`s equipment to replace "older technologies" such as DNA sequencers.
Gallahue said current NanoChip customers include the National Cancer Institute, the Mayo Clinic, and Children`s Hospital of Philadelphia, as well as various biotech and pharmaceutical companies. He estimated current markets at "several hundreds of millions of dollars," but predicted future medical diagnostics markets in the tens of billions.
Leheny, who believes Nanogen possesses "one of the more exciting technologies in what we consider to be a very exciting space," said current valuations of Nanogen are "at a pretty steep discount" despite a "very positive launch of the product." Although she declined to "put any numbers on it," she said demand for Nanogen`s instruments could "see this stock appreciate dramatically from here."

Quelle: informedinvestors.com

[ramjam]

Nicht ganz so euphorisch wie der vorige Bericht aber immerhin:

06.11.2001
Nanogen investiert bleiben
Global Net Investing

Die Experten von "Global Net Investing" raten Anlegern in der Aktie von Nanogen (WKN 911841) investiert zu bleiben.

Das Thema Terrorangriffe mit Biowaffen bleibe auf der Tagesordnung. Da die Gegenmaßnahmen zunehmend forciert würden, würden die Hersteller von Biowaffen-Detektoren weiterhin im Mittelpunkt des Anlegerinteresses stehen. Nanogen sei ein Titel, der von dieser Entwicklung mit am meisten profitieren könne. Der Titel habe zwar schon zugelegt.

Nach Ansicht der Börsenkenner von "Global Net Investing" sollen Anleger bei Nanogen unbedingt weiter dabei bleiben.

[tst89]

News, News, News....

Tuesday November 6, 7:02 am Eastern Time

Press Release
SOURCE: Nanogen, Inc.

Nanogen Launches MTHFR Protocol; Company Expands Platform Menu With Fourth DNA-Based Protocol

SAN DIEGO, Nov. 6 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that it has completed internal validation of a DNA-based research protocol for MTHFR. This is a mutation associated with cardiovascular disease and the pathology of thrombosis, for use in research laboratories on the NanoChip® Molecular Biology Workstation. The anticipated users of the protocol include genetic research labs as well as CLIA (Clinical Laboratory Improvement Act) certified laboratories that will have the option to further develop and validate these protocols for internal use in a ``home-brew`` format.

This is the fourth DNA-based research protocol that Nanogen has internally validated for use on the NanoChip® Molecular Biology Workstation. All four protocols are designed to help researchers identify genetic links in illnesses that may lead to improved treatment and preventative decisions made in patient care. The Company plans to pursue cGMP status for its facility so that it may convert the four protocols to ASR models starting in 2002.

``We are delivering on our stated commitment to aggressively develop and validate a wide menu of protocols that can be performed on our NanoChip® System,`` said Randy White, Chief Executive Officer of Nanogen. ``We believe a key factor in the adoption of the NanoChip® Workstation will be the expansion of our menu of internally validated protocols. This rapid expansion, including the analysis of mutations in both singular and multiplexed formats, helps demonstrate the flexibility and power of our electronic-based array.``

``Nanogen is the first entity to have obtained a non-exclusive license to the MTHFR mutation from Variagenics, Inc.,`` commented Taylor Crouch, Variagenics` President and CEO. ``This relationship with Nanogen represents an important step in the validation of our pharmacogenomics business model, as well as our ongoing partnership program. We believe that Nanogen`s electronics-driven technology is well-suited to help maximize the value of MTHFR polymorphism testing by providing a highly efficient and accurate system that has the potential to impact medical practice.``

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical settings. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated research protocols for the detection of the Factor II and Factor V Leiden gene mutations, a multiplexed format Factor II/Factor V gene mutation combination, and the MTHFR gene mutation, all associated with cardiovascular disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development, including ASRs, can be successfully developed and commercialized, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional assays, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

For further information please contact: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., [phone]; or Tom Baker, Media Relations of Susan E. Atkins & Associates, [phone], for Nanogen, Inc.

SOURCE: Nanogen, Inc.

[tst89]

Wednesday November 7, 7:04 am Eastern Time

Press Release
SOURCE: Susan E. Atkins & Associates

Over 100 Biotech Investors Attend Atkins & Associates Retail Conference

SAN DIEGO, Nov. 7 /PRNewswire/ -- Over 100 biotech investors from across Southern California attended Susan E. Atkins & Associates Third Annual Retail Conference today to see the presentations of six biotech and medical device companies. Held at the L`Auberge Resort & Spa, each company discussed its investment potential and the future of biotechnology. The event hosted by Atkins & Associates, San Diego`s largest science-based agency providing investor and public relations services for bio businesses, was the largest in its history.

San Diego-based companies Cypress Bioscience, Inc. (Nasdaq: CYPB - news), Vical Incorporated (Nasdaq: VICL - news), Epimmune Inc. (Nasdaq: EPMN - news), and Nanogen, Inc. (Nasdaq: NGEN - news) presented. Other presenters were Beckman Coulter (NYSE: BEC - news) of Fullerton, California and SONUS Pharmaceuticals (Nasdaq: SNUS - news) of Bothell, Washington.

``Understanding how vast the possibilities are is the key to finding the best investment opportunities in the biosciences arena,`` said Rachel Laing, editor of The T Sector and the conference`s keynote speaker. ``Investors can profit from the most profound technological revolution of our time.``

``This was a very upbeat meeting because most investors realize that the biotech sector is -- relatively speaking -- counter-cyclical,`` said Susan E. Atkins, President & CEO. ``Throughout its history, biotechnology investments have frequently run counter to the markets at large. Today is no exception.``

About Atkins & Associates

Founded in 1999, Susan E. Atkins & Associates is a consulting firm providing public and pre-public bio businesses with strategic counsel and pragmatic investor and public relations services. With a client roster of national and international accounts, Atkins & Associates has grown to nearly $3 million in annualized billings. The agency has significant experience in launching initial public offerings, corporate positioning and generating extensive awareness within the investor, business and media communities. Formore information, call Atkins & Associates at [phone] or visit the website at www.irpr.com

For further information, please contact Amber Meager of Susan E. Atkins & Associates, [phone].

SOURCE: Susan E. Atkins & Associates

[tst89]

Auch dieses will ich Euch nicht vorenthalten:

8:10AM Nanogen (NGEN) 8.20: UBS Warburg downgrades to HOLD from Strong Buy and cuts target to $7.25 from $10; says adoption of NGEN`s technology is being hampered by the lack of applications currently available; cuts FY02 revenue estimate to $10 mln from $23 mln.

______________

Trotz alledem find ich persönlich Nanogen für einen Kauf (auf langfristige Sicht hin gesehen!).

Gruß
tst

[tst89]

Variagenics, Inc. (ticker: VGNX, exchange: NASDAQ) News Release - 11/6/2001
--------------------------------------------------------------------------------
VARIAGENICS Announces Licensing Agreement With Nanogen for MTHFR Probe
CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 6, 2001--VARIAGENICS, INC. (NASDAQ:VGNX), a leader in pharmacogenomics, today announced that it has entered into a worldwide licensing agreement for VARIAGENICS ` MTHFR (methylenetetrahydrofolate reductase) patent rights with Nanogen, Inc. (NASDAQ:NGEN). Under the terms of the agreement, VARIAGENICS has granted Nanogen worldwide non-exclusive rights to commercialize home brew and analyte specific reagent tests aimed at the assessment of thrombo-embolic disease risk, among others. Additionally, the agreement stipulates that VARIAGENICS retains the rights to the development of future diagnostic tests and all other pharmacogenomic applications.
"This relationship with Nanogen represents an important step in the validation of our pharmacogenomics business model, as well as our ongoing partnership program," said Taylor Crouch, VARIAGENICS` President and CEO. "We believe that Nanogen`s electronics-driven technology is well-suited to help maximize the value of MTHFR polymorphism testing by providing a highly efficient and accurate system that has the potential to impact medical practice."
"With the addition of an internally validated research protocol for MTHFR to our NanoChip(R) System, we are delivering on our stated commitment to develop a wide menu of protocols that can be performed with our technology. The addition of MTHFR broadens the number of such Nanogen protocols associated with the detection of cardiovascular disease and the pathology of thrombosis," said Randy White, Chief Executive Officer of Nanogen. "Nanogen looks forward to expanding our relationship with Variagenics into other potential disease areas."
The MTHFR patent rights were acquired from McGill University by VARIAGENICS in 1999. Since then, VARIAGENICS and McGill University have actively collaborated in the discovery and development of pharmacogenomic markers related to this gene. Variations in the MTHFR gene are typically associated with cardiovascular disease, central nervous system disorders, osteoporosis, disorders influenced by folic acid metabolism, and cancer. Earlier prediction and/or detection of these diseases is a key focus for medical researchers, pharmaceutical companies, and treating physicians. In June 2000, the U.S. Patent and Trademark Office issued U.S. Patent 6,074,821 titled "cDNA for Human Methylenetetrahydrofolate Reductase" which was assigned to McGill University and was licensed exclusively to VARIAGENICS under the terms of the original 1999 agreement.
"When VARIAGENICS acquired the rights to MTHFR, we recognized its potential as a key element in the folate pathway, which in turn affects susceptibility to a number of diseases, as well as the pharmacokinetic and pharmacogenomic behavior of a variety of drugs," said Vincent P. Stanton, M.D., Vice President and Principal Scientist at VARIAGENICS. "We view this agreement with Nanogen as the first in many such relationships aimed at leveraging our intellectual property in the reference laboratory setting."
VARIAGENICS, INC. applies its pharmacogenomic technologies to the discovery, development and commercialization of personalized drugs and companion molecular diagnostic products. Using a drug pathway approach, the Company identifies therapeutically important genetic markers, including SNPs, haplotypes and LOH indicators. This information is then applied to clinical programs to enhance drugs in development, and ultimately to the creation of diagnostics for predicting patient response to drugs.
For more information, please visit the Company`s website at www.variagenics.com.

[tst89]

Variagenics, Inc. (ticker: VGNX, exchange: NASDAQ) News Release - 11/6/2001
--------------------------------------------------------------------------------
VARIAGENICS Announces Licensing Agreement With Nanogen for MTHFR Probe
CAMBRIDGE, Mass.--(BW HealthWire)--Nov. 6, 2001--VARIAGENICS, INC. (NASDAQ:VGNX), a leader in pharmacogenomics, today announced that it has entered into a worldwide licensing agreement for VARIAGENICS ` MTHFR (methylenetetrahydrofolate reductase) patent rights with Nanogen, Inc. (NASDAQ:NGEN). Under the terms of the agreement, VARIAGENICS has granted Nanogen worldwide non-exclusive rights to commercialize home brew and analyte specific reagent tests aimed at the assessment of thrombo-embolic disease risk, among others. Additionally, the agreement stipulates that VARIAGENICS retains the rights to the development of future diagnostic tests and all other pharmacogenomic applications.
"This relationship with Nanogen represents an important step in the validation of our pharmacogenomics business model, as well as our ongoing partnership program," said Taylor Crouch, VARIAGENICS` President and CEO. "We believe that Nanogen`s electronics-driven technology is well-suited to help maximize the value of MTHFR polymorphism testing by providing a highly efficient and accurate system that has the potential to impact medical practice."
"With the addition of an internally validated research protocol for MTHFR to our NanoChip(R) System, we are delivering on our stated commitment to develop a wide menu of protocols that can be performed with our technology. The addition of MTHFR broadens the number of such Nanogen protocols associated with the detection of cardiovascular disease and the pathology of thrombosis," said Randy White, Chief Executive Officer of Nanogen. "Nanogen looks forward to expanding our relationship with Variagenics into other potential disease areas."
The MTHFR patent rights were acquired from McGill University by VARIAGENICS in 1999. Since then, VARIAGENICS and McGill University have actively collaborated in the discovery and development of pharmacogenomic markers related to this gene. Variations in the MTHFR gene are typically associated with cardiovascular disease, central nervous system disorders, osteoporosis, disorders influenced by folic acid metabolism, and cancer. Earlier prediction and/or detection of these diseases is a key focus for medical researchers, pharmaceutical companies, and treating physicians. In June 2000, the U.S. Patent and Trademark Office issued U.S. Patent 6,074,821 titled "cDNA for Human Methylenetetrahydrofolate Reductase" which was assigned to McGill University and was licensed exclusively to VARIAGENICS under the terms of the original 1999 agreement.
"When VARIAGENICS acquired the rights to MTHFR, we recognized its potential as a key element in the folate pathway, which in turn affects susceptibility to a number of diseases, as well as the pharmacokinetic and pharmacogenomic behavior of a variety of drugs," said Vincent P. Stanton, M.D., Vice President and Principal Scientist at VARIAGENICS. "We view this agreement with Nanogen as the first in many such relationships aimed at leveraging our intellectual property in the reference laboratory setting."
VARIAGENICS, INC. applies its pharmacogenomic technologies to the discovery, development and commercialization of personalized drugs and companion molecular diagnostic products. Using a drug pathway approach, the Company identifies therapeutically important genetic markers, including SNPs, haplotypes and LOH indicators. This information is then applied to clinical programs to enhance drugs in development, and ultimately to the creation of diagnostics for predicting patient response to drugs.
For more information, please visit the Company`s website at www.variagenics.com.

[tst89]

Analyte specific reagents(ASRs) can only be sold to reference labs certified under CLIA(Clinical Lab Improvement Amendments of 1988) as high complexity labs. Nanogen is setting up the steps to deal with CLIA labs and their four new pannels are going to ASR next year. Said labs are subject to a number of requirements including the FDA`s Good Manufacturing Practices. GMP regs require among other things that medical devices be manufactured and records be maintained in specific manners ie: testing, manufacturing and control activities. Nanogen is seeking GMP clearance which is the equivalent to the coveted ISO certification sought by equipment manufacturers.
The company is partnered with Aventis and BDX who have vast experience in 510k clearance or an approved premarket approval(PMA) both of which are connected with CLIA and GMP regs. Nanogen is setting itself up to go to the FDA with certain test kits for approval/clearance afterwhich they will go to Europe and the Far East for similar status.

[tst89]

Hier ein guter Kommentar aus einem US-Board:

Long-Term Sentiment: Strong Buy
 
As PBuchta so ably pointed out, NGEN has 75.1 million in cash. They are not spending it frivolously, be assured. (Just look at the new products they have introduced recently, which they obviously made sure there was a market before prior to pursuing development of same.) The patents they have obtained are certainly nothing to sneeze at either when you take a look at where other companies trying to break into this market are going.
There`s still a lot of growing room in this sector - and NGEN has been first to market with its core product (which boasts the only 100% accuracy rate) and patents. While they aren`t turning profits YET, the time is coming. In the meantime, NGEN isn`t sitting still but positioning themselves for the future as well. If you`re a long investor, you won`t be displeased and may well be surprised just how much NGEN has going for it!

_________________

Diesem schließe ich mich voll und ganz an!

[tst89]

Search: Search

Developing BioDefenses Doesn`t Pay


Though chemical and biological weapons have been with us a long time, and the U.S. government had warned they would probably be used on American soil, the United States still has no reliable defenses against them. How can this be? The answer has a lot to do with science and profit.

It`s not for lack of money or effort that the country has no device capable of detecting a chemical or biological attack early enough for public health officials to order an evacuation. Gas masks offer peace of mind, but they do not ward off all noxious agents. Antibiotics like Zithromax, Cipro, and doxycycline are flying out of pharmacies, but they must be administered before symptoms appear. Any mail that contains mysterious white powder is likely to raise suspicions quickly, allowing disease exposure to be tested well before symptoms develop. But a larger, more stealthy attack could be devastating.

Anthrax, smallpox, and the plague are considered the most feared biological agents, and a report released in 1993 by the U.S. Congressional Office of Technology Assessment concludes that 100 kilograms of anthrax unleashed on a windless day could cause 3 million deaths. Little wonder the U.S. government wants to spend billions on more sensitive biowarfare detection devices and vaccines. As one veteran Capitol Hill press agent put it recently, "the spigots are open for any company that can produce a vaccine against a biological weapons attack."

PROFIT AND LOSSES

With that kind of money, one might think the profit motive would have taken care of this problem already. If only it were so easy. In the past, government contracts for bioterrorism defenses have not exactly attracted the Pfizers and Genentechs of the world.

A case in point is BioPort in Lansing, Michigan, a company that holds the exclusive contract to produce anthrax vaccine for the U.S. Department of Defense. In 1998, the U.S. Food and Drug Administration shuttered BioPort`s manufacturing plant because of lapses in quality control. The vaccine itself has other problems, too: for example, a company scientist died from an immune response while taking BioPort`s vaccine. Dozens of soldiers have refused to take the drug, fearing its side effects more than they do a court martial.

Unlike conventional defense contractors that live off military contracts, the biotech sector, at least for the time being, offers no convenient investment angle. The recent evanescent upticks in the share prices of Avant Immunotherapeutics (Nasdaq: AVAN), Nanogen (Nasdaq: NGEN), and Cepheid (Nasdaq: CPHD), which advanced on news of new antibioterrorism contracts, are not proof to the contrary. "For the time being, most chem-bio operations are either hidden away at huge industrial companies and make up only a tiny fraction of that firm`s total sales, or they`re at tiny, high-risk startups with few prospects of producing a real product anytime soon," says Evan Koslow, CEO of KX Industries, which makes air filters, water filters, and gas masks for the military. "Even with government contracts, it`s really tough to make big bucks in chem-bio."

No doubt this is the bigger reason that the United States is so unprepared to meet the dangers that loom ever closer.

Stephan Herrera

[e-mail]

http://www.redherring.com

[tst89]

Das muß ich hier auch noch reinstellen:

Sensationell!!!!!!

Schaut Euch mal den unten stehenden Link an! Erst graded UBS Warburg NGEN auf hold und dann decken sich die Leute damit ein?!

Wollte UBS Warburg da etwa günstig einkaufen????

Ja ja der gute alte Kostolani hatte wohl Recht mit den Analysten.....

Also streicht diese "hold"-Meldung!!!

http://www.nasdaq.com/asp/Holdings.asp?FormType=Institutiona…

Gruß
tst

[tst89]

Hier der Link zu einem weiteren neuen Patent von NGEN:

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… =AN/nanogen

[tst89]

Sorry an UBS Warburg:

Ups...hab ich mich da wohl vertan. Da hätte ich vielleicht auf das Datum schauen sollen. Was die Nasdaq alles noch unter NEWS führt.

Also der Kauf der Aktien erfolgte doch VOR dem downgraden.

tst

[tst89]

Hier News:
einfach auf 10Q klicken vomm 14.11.2001

http://www.nasdaq.com/asp/quotes_sec.asp?symbol=NGEN`&select…

Gruß
tst

P.S. Hatte selbst noch keine Zeit mir den anzuschauen.....

[tst89]

Keine News aber dafür ein interessanter Bericht, unter www.forbes.com:

Desert Blooms
Adam Leitzes and Joshua Solan, with Ben Berentson, Best of The Web, 12.03.01


In difficult markets, smart stock pickers prevail. Here are five online mavens thriving in adversity.

Goyette is the ringleader of Financial Chat, home to the ActiveTrader chat room. He oversees a diverse and occasionally rowdy group, and actively participates in the never-ending discussions. "I only have one pair of eyes," says Goyette. "But with 1,000 other pairs of eyes looking at every conceivable stock, news service and media outlet, it is very seldom that we as a group do not know why a stock is moving. More important, we often know why a stock should move before it moves."

Goyette, 31, trained at Goldman Sachs as a stock analyst and then did fixed-income arbitrage for hedge fund Mariner Investment Group before starting his own hedge fund, Delta Investment Group, in January 2000. So far this year his fund is up 95%. His investment philosophy is "to be where others are not." He attempts to uncover small-cap diamonds in the rough before anyone on Wall Street takes notice. A computer science and finance graduate of Rensselaer Polytechnic Institute, Goyette focuses on small tech companies and insists that they have sound financials. He places a particular emphasis on companies with high cash and low debt. He wants to ensure that his investments have enough capital and financial flexibility to tide them through the many months it can take before Wall Street begins to pay attention.

These days Goyette`s investment approach has him focusing on nanotechnology, the science of manufacturing devices at the subatomic level. "Nanotechnology, while still in its infancy, holds the promise to revolutionize many different aspects of our economy and civilization," says Goyette.

Favorite Stocks: Nanophase Technologies (nasdaq: NANX - news - people) and Nanogen (nasdaq: NGEN - news - people) as pure plays in the nanotechnology space. Says Goyette, "Once the average person has heard of nanotechnology, everyone will be scrambling for these types of stocks."

Vaughn Okumura
Site: www.VTOReport.com
Location: Pearl City, Hawaii

At 36, Vaughn Okumura, CPA, is retired and living in Hawaii. His story is the same as many successful individual investors: a few hard knocks at the start, "visions of losing it all" as a stock account balance was depleted and a final, miraculous recovery. Okumura says his holdings went from $35,000 to $7,000 to $2 million after taxes in a matter of ten years.

He started his site, VTO Report, in 1998 to satisfy his passion for stock investing and to teach others his technical analysis techniques. Fundamentals? "It`s like driving forward by looking in the rearview mirror," he says. On the other hand, "the chart of a stock will give you clues as to how a particular company is operating long before it reports its earnings."

Okumura`s most successful strategy outlined on the site is his short-term trades of the Nasdaq 100 index. Up 10% year-to-date and 184% since 1997, the portfolio uses a simple relative strength indicator to determine when the market is overbought and oversold. His site`s "smooth" stocks are consistent winners over many years. "Most investors buy stocks in a downtrend thinking they`ve uncovered a bargain," he cautions. "But in most cases, they end up with a portfolio of clunkers."

Favorite Stocks: Harley-Davidson (nyse: HDI - news - people), Stryker (nyse: SYK - news - people) and Sysco (nyse: SYY - news - people). "All three have been in nonvolatile uptrends over the last 15 years."

[tst89]

Hier wieder ein neues Patent von NGEN:

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… =AN/nanogen

[tst89]

Friday November 23, 12:41 pm Eastern Time

UK`s Oxford Gene Technology wins chip patent case

LONDON, Nov 23 (Reuters) - The European Patent Office has found in favour of Oxford Gene Technology after a six-year dispute over its patent for ``gene chips``, the UK firm said on Friday.

The patent was opposed by seven companies including Affymetrix Inc (NasdaqNM:AFFX - news), Abbott Laboratories Inc (NYSE:ABT - news), Roche Holding AG and Nanogen Inc (NasdaqNM:NGEN - news), although Affymetrix withdrew its opposition after a settlement in March this year.

Professor Ed Southern, owner of OGT and the patent`s inventor, said the decision ``greatly strengthens the patent, and we intend to pursue the many licensing opportunities with renewed determination``.

Microarrays are biological chips used by researchers to sort genes in a DNA sample. A recent report predicted that the microarray market would reach about $536 million by 2005, with an annual growth rate of 18.9 per cent.

[tst89]

Friday, Nov 30, 2001

Nanogen, Inc Financials - EDGAR Online Financials

http://biz.yahoo.com/fin/l/n/ngen.html

[tst89]

Ein neues Patent vom 29.11.

http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=… &RS=AN/nanogen

Und eins vom 04.12.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… ogen/becton&RS=AN/nanogen/becton

[tst89]

Thursday December 6, 7:00 am Eastern Time

Press Release
SOURCE: Nanogen, Inc.

Nanogen and RationalDiagnostics Initiate Research Under Development Site Agreement

- RationalDiagnostics to Use Nanogen`s Workstation to Develop Sophisticated Lymphoma Diagnostic Test -

SAN DIEGO and SEATTLE, Dec. 6 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news), and RationalDiagnostics, LLC, a privately-held clinical genomics company, announced the initiation of research under a development site agreement entered into earlier this year. The agreement intends to expand the applications of the NanoChip® Molecular Biology Workstation with a focus on developing a gene-based microarray designed to diagnose a variety of lymphomas. Under the terms of the agreement, RationalDiagnostics will provide its expertise in identifying genes that serve as novel disease markers in exchange for access to a NanoChip® Workstation. After the planned research is completed, Nanogen has certain rights to commercialize any assays developed by RationalDiagnostics using the NanoChip® Workstation and RationalDiagnostics may purchase the Workstation for use in its operations.

``Nanogen`s decision to select RationalDiagnostics as a development site, we believe, is a testament to our capabilities to discover relevant (genetic) content for use in molecular diagnostics applications for personalized medicine and represents an important step in the Company`s efforts to develop a genechip for the detection of a variety of lymphomas,`` said Bill Connors, RationalDiagnostics Interim CEO and co-founder. ``The Workstation provides us with the means to rapidly develop genechip-based diagnostic prototypes on the NanoChip®, which we believe is an ideal platform based on the technology`s speed, accuracy and ease of use.``

There is currently a growing demand by both patients and physicians to better understand disease prognosis and management. Due to the complexity of many genetic-based diseases such as lymphoma, gene-based molecular diagnostics have the potential to provide relevant information which may lead to improved patient outcome. RationalDiagnostics` approach to developing molecular diagnostics is based on the study and analysis of patient specimens of diseased cells. By identifying those genes that are irregularly over or under expressed in diseased cells when compared to healthy cells, RationalDiagnostics can develop clinical laboratory tools based on DNA arrays (genechips) like the NanoChip® system, containing probes (fragments of DNA) of disease relevant genes. Tests like these may yield more valuable diagnostic and prognostic information.

``RationalDiagnostic`s expertise in clinical genomics research was an important factor in our decision to enter into the development site agreement as its three-step process for identifying disease specific genes relies on the use of multiple patients` specimens, resulting in more accurate gene expression data,`` said V. Randy White, CEO of Nanogen. ``This agreement is a model for how we anticipate developing future applications for the NanoChip® System as a potential tool for molecular diagnostics. As such, we look forward to this agreement as it allows us to venture with RationalDiagnostics into the lymphoma market segment, for which there are currently no commercially available genechip-based diagnostics.``

About RationalDiagnostics

RationalDiagnostics is a clinical genomics company devoted to developing novel diagnostic tools based on the discovery of disease-specific genes. RationalDiagnostics` core expertise is to (a) identify common conditions for which better diagnostic tests are needed, (b) use advances in genomic technology to identify diagnostic gene products, and (c) validate the utility of novel diagnostic tools. Better diagnostic tools are expected to improve patient management and reduce health costs. They may also yield molecular targets that will be useful in developing new drug treatments. The company was founded in 2000 by Daniel Sabath, M.D., Ph.D., Stephen Schmechel, M.D., Ph.D. and William Connors, J.D., C.P.A. For more information, visit www.rationaldiagnostics.com .

About Nanogen

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated research protocols for the detection of the Factor II and Factor V Leiden gene mutations, a multiplexed format Factor II/Factor V gene mutation combination, and the MTHFR gene mutation, all associated with cardiovascular disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® is intended for research use only and not for use in diagnostic procedures. For more information, visit www.nanogen.com .

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether Nanogen`s development site agreements may result in sales of the NanoChip® Workstations, whether Nanogen`s products under development, including ASRs, can be successfully developed and commercialized, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional assays, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® Workstation, whether results reported by Nanogen`s customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Nanogen, Inc.

[tst89]

Den ganzen Text gibts bei http://www.italheartj.org/ -einfach den Link "Last Issue" anklicken!


"Microarray-based genetic analyses for studying susceptibility to arterial and venous thrombotic disorders

Eleanor S. Pollak* § , Lana Feng**, Halleh Ahadian**, Paolo Fortina §

*Department of Pathology and Laboratory Medicine, § Department of Pediatrics, University of Pennsylvania School of Medicine and The Children’s Hospital of Philadelphia, Philadelphia, PA, **Nanogen, Inc., San Diego, CA, USA

We describe the potential of microarray technology for parallel, high-throughput approaches to molecular detection of DNA variations associated with progression to arterial and venous thrombotic diseases. The use of the newly commercialized NanoChip TM platform and a framework for genetic screening with a list of potential genetic targets useful to the evaluation of cardiovascular risk are presented. Implementation in clinical setting of analytical silicon and glass microarrays will facilitate early diagnosis, help direct specific advice to high-risk individuals and evaluate treatment strategies.
(Ital Heart J 2001; 2 (8): 568-572)"

[tst89]

Guten Morgen zusammen!

Hier wieder ein neues Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… =AN/nanogen

[tst89]

Thursday December 20, 7:00 am Eastern Time

Press Release
SOURCE: Nanogen, Inc.

Nanogen Launches Hereditary Hemochromatosis Protocol

- Company Expands Platform Menu With Fifth DNA-Based Protocol -

SAN DIEGO, Dec. 20 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that it has completed internal validation of a DNA-based research protocol for a mutation (S65C) associated with Hereditary Hemochromatosis (``HH``), a disorder that causes excess iron to be stored in cells of the liver, heart, pancreas and other organs. The protocol is for use in research laboratories on the NanoChip® Molecular Biology Workstation. The anticipated users of the protocol include CLIA (Clinical Laboratory Improvement Act) certified laboratories that will have the option to further develop and validate the protocol for internal use in a ``home-brew`` format.

The Company has now internally validated five DNA-based research protocols for use on the NanoChip® Molecular Biology Workstation: Factor II, Factor V, a Factor II and Factor V multiplex format, and MTHFR, all of which are associated with cardiovascular disease, and now HH. These protocols are designed to help researchers identify genetic links in illnesses that may lead to improved treatment and prevention decisions made in patient care.

``The HH protocol is the fifth protocol that Nanogen has internally validated this year.This meets our stated projections for 2001 and demonstrates the significant progress we have made toward expanding the utility of our NanoChip® platform,`` said V. Randy White, Chief Executive Officer of Nanogen. ``We expect to convert certain protocols to an ASR model in 2002 once the Company achieves cGMP status for its facilities. It is important to note, however, that we will continue to aggressively develop and internally validate a wide menu of protocols that can be performed on our platform and, due to the flexibility of our platform, we expect partners and customers to continue validating their own test protocols. We believe one of the key factors in the adoption of the NanoChip® Workstation will be the expansion of our menu of protocols. As our menu expands, so does the total benefit of the NanoChip® platform.``

Although HH is one of the most common genetic disorders in the United States, it remains underdiagnosed. Men are about five times as likely to be diagnosed with HH as women due to the loss of iron through menstrual cycles and pregnancy. Men tend to develop symptoms between 40 and 60 years of age while women develop symptoms after menopause. Without proper treatment, the excess iron storage associated with HH can lead to progressive skin pigmentation, cirrhosis, diabetes, arthritis and even death. If detected early, HH is treatable by a process called phlebotomy in which blood is removed. The goal of the treatment is to bring blood iron levels to the low end of the normal range and keep them there.

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochomatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether customers will develop their own protocols on the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols or achieving cGMP status, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Nanogen, Inc.

[tst89]

http://www.lab-on-a-chip.com/publications/evalrev4.htm

SNP/MUTATION DISCRIMINATION IN HUMAN GENES BY A MICROARRAY APPROACH

Abstract, presented at: Advanced technology and Biotechnology for Laboratory Medicine and Hospital Automation. Oct 3 - 5 2001 in Milan.

SNP/MUTATION DISCRIMINATION IN HUMAN GENES BY A MICROARRAY APPROACH

Foglieni B1, Stenirri S1, Santacroce R2, Ratti A3, Margaglione M4, Dallapiccola B5, Travi M6, Pollak E2, Fortina P2, Ferrari M1.
1Unit of Genomics for Diagnosis of Human Pathologies, IRCCS H. S. Raffaele, Milan, Italy; 2The Children`s Hospital of Philadelphia, PA, USA; 3Ospedale Maggiore Policlinico, University of Milan, Italy; 4IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 5Istituto CSS Mendel, University La Sapienza, Roma, Italy; 6Azienda Ospedaliera ICP, Dipartimento di Medicina di Laboratorio, Laboratorio di Genetica Medica, Milan, Italy.

Microchip-based nucleic acid technology has potential for sample preparation and detection in integrated systems and permits the rapid analysis of genetic information by miniaturization of many cumbersome techniques. Currently, the main focus of DNA-chip work is in the fields of genomics, gene discovery and diagnostics, in order to develop assays which allow the rapid detection of many SNPs in a large population.

We evaluated the NMW 1000 NanoChipTM Molecular Biology Workstation (Nanogen, San Diego, CA) for the development of analytical assays to identify different kinds of mutations in several genes. This technology is based on the electronic manipulation of an electric field in a semiconductor device. Through the use of microelectronics, Nanogen`s technology enables the active movement and concentration of charged molecules to and from designated test sites. The biotinyled amplicon is electronically placed on the chip and electrophoresed to selected pads by positive bias direct current, where it remains embedded through interaction with streptavidin in the permeation layer. The DNA at each pad is then hybridized to a mixture of oligonucleotide probes, specific for either the wild-type or the mutant sequence, labeled with the fluorescent tags Cy3 and Cy5. Single base pair mismatched probes are then preferentially denatured with the application of an increasing temperature on the chip. After this step of thermal stringency, the array is imaged and the fluorescence quantified. An advanced multi-tasking operating system controls all specific aspects of machine operation, including assay operation, fluorescent signal detection, signal processing and data analysis.
The test sites can be arranged in a variety of configurations on the microchip, combining the potential for rapid throughput screening with the flexibility to customize chip for genes of interest. In addition, Nanogen system allows for the simultaneous analysis of multiple test results, or "multiplexing", from a single sample.

We developed rapid assays for mutation detection that utilize this technology. A retrospective analysis was performed for SNPs/mutations within the Human Factor VII, Factor V Leiden, methylenetetrahydrofolate reductase (MTHFR), Protein C, and beta-globin genes. For each situation, we applied thermal stringency until the mismatched controls had been removed to background levels. For all assays, the complete scanning of the chip was finished in approximately 5 min and the whole analytical process was accomplished in 15 min. The great flexibility of this system allowed us the simultaneous use of a wide variety of probes of different content, length and chemical composition on the same chip. Quantification of the fluorescence emitted from each sample indicated a greater than 10-fold signal to noise ratio thus allowing complete discrimination between the matched reporter probes and the mismatched ones. The method was validated by the accurate discrimination of more than 450 blinded DNA samples, with 100% concordance observed. The technology enabled the rapid genotyping of a large number of samples for multiple genes in the same assay. The active hybridization approach exceeds many of the limitations of the passive hybridization processes and can significantly improve the performance of DNA array analysis for a variety of diagnostic purposes. The application of electronics may ultimately lead to complete automation in view of a laboratory-on-a-chip technology.

[ambobobo]

@tst89

Hallo
heute war kein guter Tag für Nanogen
ich warte immer noch auf meine Chance
bei Nanogen zur Zeit bin ich wieder
in Plug Power heute nette 40% und Schluss
auf Tageshoch aber wie immer ein Auge auf Nanogen

bobo

[BizAngel]

Hallo zusammen,

wir bauen zur Zeit eine Seite über Nanotechnologie Aktien - und suchen noch Mitstreiter.

Habt Ihr Lust, als Moderatoren den Unternehmensbereich Nanogen zu betreuen?

Bei Interesse meldet Euch doch kurz per Boardmail oder an [e-mail]

[DagobertDag]

Hallo zusammen

@ BizAngel
Nur zur Erinnerung.!! Nanogen hat nichts mit Nanotechnologie zu tun. Gehört eindeutig in die Biotechbranche.

Da ich aber an der Nanotechnologie interessiert bin würde ich mal mehr Informationen zu deiner Nanotechnologieseite erfahren.?!

Gruß

[tst89]

@BizAngel

Mehr Infos bitte über Deine Seite......
zuerst sollte jedoch geklärt werden ob Nanogen tatsächlich auf
diese Seite gehört.

Ansonsten spricht sicherlich nix dagegen...

Ein 3er-Moderatoren Trio mit Dagobert, Ambobobo und mir wäre
sicher interessant.

Gruß
tst

[Dan19]

Kann Nanogen nochmal auf 20 $ steigen ? Wie hoch steht Ihr die Chancen hierfür ?

Danke im voraus

Daniel

[BizAngel]

Hallo tst89 und DagobertDag,

guckt mal in Eure Board Mail.

[tst89]

@dan19

Natürlich kann (und wird) NGEN nochmal auf 20$ steigen. Es ist
nur eine Frage der Zeit. Überleg Dir mal wo die Nasdaq im Februar 2000
war und wo NGEN mal seinen Höchststand hatte. NGEN war bei ca. 120$ und selbst
wenn es nur noch 1/3 von seinem Höchststand erreichen würde dann wären wir bei
lockeren 40$.

Ich selbst halte - eine positive Entwicklung der Nasdaq vorausgesetzt - ein
12 Monats-Kursziel von ca. 25$ für realistisch.

Nanogen ist ein sicherer "strong buy" - allerdings sicherlich
nur für Leute die neben Geld auch noch einiges an Zeit investieren
können. Das muß jedoch jeder für sich entscheiden. Wer nur kurz in NGEN
investieren will dem müssen sehr geringe Gewinne reichen....wer jedoch Zeit
hat und nach und nach NGEN`s kauft.....

Gruß
tst

[ambobobo]

@ tst89

Du hast Boardmail !!!!!


bobo

[ambobobo]

@ all

Was ist mit Greensspan los das erste mal was
gutes von Ihm gehört


bobo

[DagobertDag]

Hallo

Der Vertrauensmissbrauch von ImClone liegt ziehmlich schwer auf dieser Branche. Darum denke ich dass Biotech-Aktien einige Zeit underperformen. Obwohl es ja auch schon wieder fast einen halben Monat her ist, dass ImClone`s Medikament abgewiesen ist.Aber wie das Management die ganze Sache angegangen ist riecht nach Betrug.!
Also erhöhte Wachsamkeit und nicht immer alles glauben was uns die Vorstände weiß machen wollen.
Aber das sind wir ja auch von Neuer-Markt Unternehmen gewohnt.

Gruß

[tst89]

Thursday January 24, 8:47 am Eastern Time

Press Release

SOURCE: Nanogen, Inc.

Nanogen to Hold Conference Call on 2001 Year-End
and Fourth Quarter Financial Results

Thursday, January 31, 2002 at 4:30 p.m. ET -1:30 p.m. PT-

SAN DIEGO--(BUSINESS WIRE)--Jan. 24, 2002--Nanogen, Inc. (Nasdaq:NGEN - news) will hold a conference call on
Thursday, January 31, 2002 at 4:30 p.m. Eastern Time to discuss 2001 year-end and fourth quarter financial results. The
earnings release will be issued at close of market January 31, 2002

Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast
on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until February 14,
2002.

Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity
and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The
Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to
develop applications for future clinical use. To date, the Company has developed and internally validated five research
protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most
common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and
genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For
additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results
to differ materially from those set forth in the forward-looking statements, including whether Nanogen`s development site
agreements may result in sales of the NanoChip® Workstations, whether Nanogen`s products under development, including
ASRs, can be successfully developed and commercialized, whether regulatory clearances or approvals will be obtained,
whether Nanogen will be successful in developing additional assays, whether Nanogen will be successful in developing FDA
approved molecular diagnostic tests utilizing the NanoChip® Workstation, whether results reported by Nanogen`s customers
or partners can be identically replicated, and other risks and uncertainties discussed under the caption ``Factors That May
Affect Results`` and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2000, as amended, filed with the
Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims
any intent or obligation to update these forward-looking statements.

[tst89]

Na heute +14,4% in Frankfurt......

nicht schlecht.....